drugset / Trial / NCT04274426
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Timeline
- Start
- 2021-10-13
- Primary completion
- 2025-12-03
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 4 unknown | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 6 mg/kg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |